• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Wednesday's Intraday Session

    5/3/23 1:31:31 PM ET
    $ACGN
    $AKAN
    $APM
    $IMGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $ACGN alert in real time by email

    Gainers

    • Immunogen (NASDAQ:IMGN) shares rose 126.1% to $11.76 during Wednesday's regular session. As of 13:30 EST, Immunogen's stock is trading at a volume of 84.0 million, which is 2278.8% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $2.6 billion. As per the press release, Q1 earnings came out 3 days ago.
    • Aptorum Gr (NASDAQ:APM) shares rose 106.59% to $5.97. The current volume of 13.0 million shares is 19580.9% of Aptorum Gr's average full-day volume over the last 100 days (last updated at 13:30 EST). The company's market cap stands at $21.3 million.
    • Aceragen (NASDAQ:ACGN) stock moved upwards by 83.73% to $3.05. As of 13:30 EST, this security is trading at a volume of 14.0 million shares, making up 77228.4% of its average full-day volume over the last 100 days. The company's market cap stands at $25.6 million.
    • Kiromic BioPharma (NASDAQ:KRBP) stock moved upwards by 50.7% to $5.38. As of 13:30 EST, this security is trading at a volume of 6.2 million shares, making up 3804.1% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $5.2 million.
    • Mersana Therapeutics (NASDAQ:MRSN) shares moved upwards by 46.11% to $6.4. Trading volume for this security as of 13:30 EST is 11.2 million, which is 843.9% of its average full-day volume over the last 100 days. The company's market cap stands at $698.0 million.
    • Akanda (NASDAQ:AKAN) shares moved upwards by 46.05% to $1.62. Akanda's stock is trading at a volume of 32.1 million shares as of 13:30 EST. This is 10461.2% of its average full-day volume over the last 100 days. The company's market cap stands at $5.5 million.

    Losers

    • Assure Hldgs (NASDAQ:IONM) shares decreased by 34.9% to $2.39 during Wednesday's regular session. Assure Hldgs's stock is trading at a volume of 162.0K shares as of 13:30 EST. This is 109.2% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $2.6 million.
    • NeuroMetrix (NASDAQ:NURO) stock fell 28.06% to $1.0. Trading volume for this security as of 13:30 EST is 263.0K, which is 1172.7% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $7.7 million. The company's, Q1 earnings came out today.
    • Intelligent Bio Solutions (NASDAQ:INBS) stock declined by 24.86% to $2.57. As of 13:30 EST, this security is trading at a volume of 1.0 million shares, making up 1392.1% of its average full-day volume over the last 100 days. The company's market cap stands at $4.0 million.
    • Portage Biotech (NASDAQ:PRTG) shares decreased by 21.86% to $2.86. As of 13:30 EST, this security is trading at a volume of 56.7K shares, making up 201.2% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $49.7 million.
    • Magenta Therapeutics (NASDAQ:MGTA) stock decreased by 20.81% to $0.61. Trading volume for Magenta Therapeutics's stock is 4.9 million as of 13:30 EST. This is 378.5% of its average full-day volume over the last 100 days. The company's market cap stands at $36.9 million.
    • Sunshine Biopharma (NASDAQ:SBFM) stock fell 18.65% to $0.48. The current volume of 449.0K shares is 365.2% of Sunshine Biopharma's average full-day volume over the last 100 days (last updated at 13:30 EST). The company's market cap stands at $10.8 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ACGN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ACGN
    $AKAN
    $APM
    $IMGN

    CompanyDatePrice TargetRatingAnalyst
    Mersana Therapeutics Inc.
    $MRSN
    2/6/2025Outperform
    William Blair
    Mersana Therapeutics Inc.
    $MRSN
    11/15/2024$5.00Buy
    Citigroup
    Mersana Therapeutics Inc.
    $MRSN
    3/19/2024$5.00Underweight → Neutral
    JP Morgan
    Mersana Therapeutics Inc.
    $MRSN
    2/29/2024$6.00Neutral → Buy
    BTIG Research
    Mersana Therapeutics Inc.
    $MRSN
    2/29/2024$7.00Neutral → Buy
    Guggenheim
    Mersana Therapeutics Inc.
    $MRSN
    2/29/2024$2.00 → $7.00Neutral → Outperform
    Wedbush
    Mersana Therapeutics Inc.
    $MRSN
    12/4/2023$1.00 → $5.00Neutral → Buy
    Citigroup
    ImmunoGen Inc.
    $IMGN
    12/1/2023$25.00 → $31.00Buy → Neutral
    Guggenheim
    More analyst ratings

    $ACGN
    $AKAN
    $APM
    $IMGN
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    March 26, 2024 - FDA Roundup: March 26, 2024

    For Immediate Release: March 26, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  On Monday, the FDA proposed a ban of electrical stimulation devices intended to reduce or stop self-injurious or aggressive behavior, a step rarely taken by the agency. The agency has determined that these devices present an unreasonable and substantial risk of

    3/26/24 3:38:14 PM ET
    $IMGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for ELAHERE issued to IMMUNOGEN INC

    Submission status for IMMUNOGEN INC's drug ELAHERE (SUPPL-5) with active ingredient MIRVETUXIMAB SORAVTANSINE-GYNX has changed to 'Approval' on 03/22/2024. Application Category: BLA, Application Number: 761310, Application Classification:

    3/22/24 1:48:21 PM ET
    $IMGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for ELAHERE issued to IMMUNOGEN INC

    Submission status for IMMUNOGEN INC's drug ELAHERE (ORIG-1) with active ingredient MIRVETUXIMAB SORAVTANSINE-GYNX has changed to 'Approval' on 11/14/2022. Application Category: BLA, Application Number: 761310, Application Classification:

    11/15/22 5:01:07 PM ET
    $IMGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACGN
    $AKAN
    $APM
    $IMGN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Hrt Financial Lp bought $40,650 worth of Class A Shares (29,036 units at $1.40) and sold $10,150 worth of Class A Shares (7,868 units at $1.29) (SEC Form 4)

    4 - AKANDA CORP. (0001888014) (Issuer)

    1/20/26 2:07:19 PM ET
    $AKAN
    Medicinal Chemicals and Botanical Products
    Health Care

    Chief Executive Officer Bersani Pietro bought $7,407 worth of shares (3,488 units at $2.12), increasing direct ownership by 3% to 142,333 units (SEC Form 4)

    4 - Kiromic Biopharma, Inc. (0001792581) (Issuer)

    8/26/24 6:44:11 PM ET
    $KRBP
    Medicinal Chemicals and Botanical Products
    Health Care

    Chief Financial Officer Hungerford Brian bought $8,802 worth of shares (4,000 units at $2.20), increasing direct ownership by 7% to 64,933 units (SEC Form 4)

    4 - Kiromic Biopharma, Inc. (0001792581) (Issuer)

    8/21/24 4:29:54 PM ET
    $KRBP
    Medicinal Chemicals and Botanical Products
    Health Care

    $ACGN
    $AKAN
    $APM
    $IMGN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Akanda Corp. Driving Recurring Revenue Growth: $2 Million Cash Flow Secured Through Fiber Acquisition

    Toronto, Ontario--(Newsfile Corp. - March 26, 2026) - Akanda Corp. (NASDAQ:AKAN) ("Akanda") and its wholly owned subsidiary, First Towers & Fiber Corp. ("FTF" or the "Company"), an emerging telecommunications infrastructure developer in Mexico, are pleased to announce an expansion of its dark fiber network with the addition of approximately 200 kilometres, increasing total network coverage to approximately 900 kilometres across Central Mexico.This milestone is expected to materially advance FTF's strategy to build a scaled, high-margin, cash-flow-generating digital infrastructure platform in what the Company believes is one of Latin America's most attractive and undersupplied connectivity ma

    3/26/26 8:30:00 AM ET
    $AKAN
    Medicinal Chemicals and Botanical Products
    Health Care

    Intelligent Bio Solutions Strengthens European IP Portfolio with Eighth Patent Grant

    NEW YORK, March 26, 2026 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (NASDAQ:INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced it has received European Patent EP3752831, related to contextualizing fingerprint chemical analysis with fingerprint deposition volume. The grant marks the Company's eighth European patent, further enhancing intellectual property rights around its fingerprint sweat drug testing technology. The newly granted patent protects a key advancement in how the Company's technology analyzes substances detected in fingerprint sweat by correlating chemical findings with the volum

    3/26/26 8:30:00 AM ET
    $INBS
    Medical/Dental Instruments
    Health Care

    Aptorum Group and DiamiR Biosciences Announce Publication of microRNA Glioblastoma Biomarker Study in Diagnostics in Collaboration with the University of Pennsylvania

    NEW YORK, NY; NEW HAVEN, CT; and PRINCETON, NJ, March 10, 2026 (GLOBE NEWSWIRE) -- Aptorum Group Limited (NASDAQ:APM) ("Aptorum Group" or "Aptorum"), a clinical stage biopharmaceutical company dedicated to addressing unmet medical needs, and DiamiR Biosciences Corp. ("DiamiR"), a developer of innovative blood-based diagnostic tests for brain health and other diseases, today announced the publication of a paper by Giliberto, et. al. titled "Development of microRNA-Based Glioblastoma Biomarkers Using Blood Plasma Specimens" in Diagnostics, (https://doi.org/10.3390/diagnostics16050791), a leading peer-reviewed journal focused on clinical diagnostics and biomarker research. This study, condu

    3/10/26 8:00:00 AM ET
    $APM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACGN
    $AKAN
    $APM
    $IMGN
    SEC Filings

    View All

    $ACGN
    $AKAN
    $APM
    $IMGN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    $ACGN
    $AKAN
    $APM
    $IMGN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 20-F filed by Aptorum Group Limited

    20-F - Aptorum Group Ltd (0001734005) (Filer)

    3/27/26 4:02:32 PM ET
    $APM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form 6-K/A filed by Aptorum Group Limited

    6-K/A - Aptorum Group Ltd (0001734005) (Filer)

    3/26/26 4:30:08 PM ET
    $APM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Intelligent Bio Solutions Inc. filed SEC Form 8-K: Leadership Update, Other Events, Financial Statements and Exhibits

    8-K - INTELLIGENT BIO SOLUTIONS INC. (0001725430) (Filer)

    3/23/26 4:30:22 PM ET
    $INBS
    Medical/Dental Instruments
    Health Care

    William Blair initiated coverage on Mersana Therapeutics

    William Blair initiated coverage of Mersana Therapeutics with a rating of Outperform

    2/6/25 7:08:59 AM ET
    $MRSN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Citigroup resumed coverage on Mersana Therapeutics with a new price target

    Citigroup resumed coverage of Mersana Therapeutics with a rating of Buy and set a new price target of $5.00

    11/15/24 8:15:56 AM ET
    $MRSN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Mersana Therapeutics upgraded by JP Morgan with a new price target

    JP Morgan upgraded Mersana Therapeutics from Underweight to Neutral and set a new price target of $5.00

    3/19/24 7:51:31 AM ET
    $MRSN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Boyages Steven Constantine

    4 - INTELLIGENT BIO SOLUTIONS INC. (0001725430) (Issuer)

    3/20/26 5:00:35 PM ET
    $INBS
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Hurd Jonathan Scott

    4 - INTELLIGENT BIO SOLUTIONS INC. (0001725430) (Issuer)

    3/20/26 5:00:31 PM ET
    $INBS
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Sakiris Spiro Kevin

    4 - INTELLIGENT BIO SOLUTIONS INC. (0001725430) (Issuer)

    3/20/26 5:00:32 PM ET
    $INBS
    Medical/Dental Instruments
    Health Care

    $ACGN
    $AKAN
    $APM
    $IMGN
    Leadership Updates

    Live Leadership Updates

    View All

    Sunshine Biopharma Announces the Appointment of New Chief Commercial Officer

    FORT LAUDERDALE, FL / ACCESSWIRE / January 15, 2025 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals is pleased to announce the appointment of Mr. Michel Roy as its new Chief Commercial Officer (CCO), effective immediately. Mr. Roy brings a wealth of experience and a proven track record of success in driving commercial growth and strategic initiatives.In this role, Mr. Roy will be responsible for overseeing the Company's commercial strategy, including sales, marketing, and business development. With over 20 years of experience in the pharmaceutic

    1/15/25 8:00:00 AM ET
    $SBFM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Portage Biotech Announce Re-Launch of Adenosine Subsidiary as Independently Managed Company; Appointment of Peter Molloy to Lead New Company

    WESTPORT, Conn., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Portage Biotech, Inc. ("Portage" or the "Company") (NASDAQ:PRTG), a clinical-stage immuno-oncology company with a portfolio of innovative therapeutics, today announced the re-launch of its wholly-owned subsidiary as an independently managed company focused on developing best-in-class adenosine receptor antagonists. Peter Molloy has been appointed Chief Executive Officer of the subsidiary, to be named Cyncado TherapeuticsTM, Inc. As CEO, Mr. Molloy will lead efforts to secure external financing directly into Cyncado and to advance the clinical development of its portfolio of A2a and A2b receptor antagonists. These therapeutics are distin

    1/6/25 5:00:49 AM ET
    $PRTG
    Oil & Gas Production
    Energy

    PureTech Founded Entity Seaport Therapeutics Names Lauren White as Chief Financial Officer

    Former ImmunoGen CFO will join Seaport to steer capital financing strategy, accounting, FP&A and investor relations PureTech Health plc (NASDAQ:PRTC, LSE: PRTC)) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company, noted that its Founded Entity, Seaport Therapeutics, ("Seaport") a biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced the appointment of Lauren White as Chief Financial Officer. An accomplished biotech financial executive, Ms. White most recently served as the Chief Financial Officer at ImmunoGen (NASDAQ:IMGN) prior to its acquisition by AbbVie (NYSE:ABBV) for $10.1 billion in 2024. T

    11/5/24 7:05:00 AM ET
    $ABBV
    $CCCC
    $IMGN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    $ACGN
    $AKAN
    $APM
    $IMGN
    Financials

    Live finance-specific insights

    View All

    Intelligent Bio Solutions Reports Record Fiscal Second Quarter Revenue Growth of 48% with Reader Sales Surging 104% Year-Over-Year

    First half fiscal 2026 revenue surpasses $2 million, up 36% year-over-year  Reader sales more than double to 104% year-over-year for the second quarter, demonstrating razor-razorblade model momentum Gross profit margins for first half fiscal 2026 increased 10% year-over-year to 49%, reflecting improved operational efficiency Current assets balance of $12.17 million as of December 31, 2025, including $9.40 million receivable in connection with the private placement of securities that closed on January 2, 2026. NEW YORK, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (NASDAQ:INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, no

    2/12/26 8:30:00 AM ET
    $INBS
    Medical/Dental Instruments
    Health Care

    Mersana Therapeutics Provides Business Update and Announces Third Quarter 2025 Financial Results

    Day One Biopharmaceuticals, Inc. to Acquire Mersana Therapeutics, Inc.Agreement provides for upfront consideration of $25.00 per share in cash, plus potential contingent value rights cash payments of up to an aggregate of $30.25 per share, for aggregate deal value of up to approximately $285 millionClosing is expected to occur by the end of January 2026 CAMBRIDGE, Mass., Nov. 14, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on the development of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today provided a business update and reported financial results for the third quarter e

    11/14/25 7:00:00 AM ET
    $MRSN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Intelligent Bio Solutions Reports Fiscal 2026 First Quarter Financial Results and Operational Highlights, Delivering Record Revenue Growth

    Record quarterly revenue of $1.11 million, an increase of 32% sequentially and 28% year-over-year, driven by consumable cartridge sales and customer base expansion Gross profit margins increased 690 basis points year-over-year to 46.6%, reflecting improved operational efficiency and greater revenue percentage from higher margin cartridge sales NEW YORK, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (NASDAQ:INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced its financial results and operational highlights for the fiscal first quarter ended September 30, 2025. The fiscal 2026 first

    11/12/25 8:30:00 AM ET
    $INBS
    Medical/Dental Instruments
    Health Care

    $ACGN
    $AKAN
    $APM
    $IMGN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Mersana Therapeutics Inc.

    SC 13D/A - Mersana Therapeutics, Inc. (0001442836) (Subject)

    11/15/24 4:45:57 PM ET
    $MRSN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Intelligent Bio Solutions Inc.

    SC 13G/A - INTELLIGENT BIO SOLUTIONS INC. (0001725430) (Subject)

    11/14/24 7:16:17 PM ET
    $INBS
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Mersana Therapeutics Inc.

    SC 13G/A - Mersana Therapeutics, Inc. (0001442836) (Subject)

    11/14/24 5:45:55 PM ET
    $MRSN
    Biotechnology: Pharmaceutical Preparations
    Health Care